AIM ImmunoTech
About: AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
Employees: 28
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
6% more funds holding
Funds holding: 33 [Q3] → 35 (+2) [Q4]
8.49% less ownership
Funds ownership: 15.77% [Q3] → 7.29% (-8.49%) [Q4]
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
62% less capital invested
Capital invested by funds: $2.43M [Q3] → $919K (-$1.51M) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for AIM.
Financial journalist opinion
Based on 3 articles about AIM published over the past 30 days
Neutral
Seeking Alpha
11 hours ago
AIM ImmunoTech Inc. (AIM) Q4 2024 Earnings Call Transcript
AIM ImmunoTech Inc. (NYSE:AIM ) Q4 2024 Earnings Conference Call April 1, 2025 8:30 AM ET Company Participants Thomas Equels - Chief Executive Officer, President and Executive Vice Chairman Conference Call Participants Ed Woo - Ascendiant Capital Markets Operator Hello and welcome to the AIM ImmunoTech Fourth Quarter and Full Year 2024 Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode.
Neutral
Seeking Alpha
4 days ago
Aimia Inc. (AIMFF) Q4 2024 Earnings Call Transcript
Aimia Inc. (OTCPK:AIMFF) Q4 2024 Results Conference Call March 28, 2025 8:30 AM ET Company Participants Joe Racanelli - Vice President of Investor Relations Tom Finke - Executive Chairman Rhys Summerton - Incoming Executive Chairman Steven Leonard - President and Chief Financial Officer Conference Call Participants Brian Morrison - TD Cowen Operator Good morning, ladies and gentlemen, and welcome to Aimia Inc. Fourth Quarter 2024 Results Conference Call. At this time, all lines are in listen-only mode.
Neutral
GlobeNewsWire
3 weeks ago
AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
On-demand video webcast now available
Neutral
GlobeNewsWire
1 month ago
AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza
Proposed study of Ampligen as a vaccine adjuvant to increase cross-reactivity to influenza strains Proposed study of Ampligen as a vaccine adjuvant to increase cross-reactivity to influenza strains
Neutral
GlobeNewsWire
1 month ago
AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance
OCALA, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it received notice from the NYSE American (the “American”) that the American has accepted the Company's Plan to regain compliance with the minimum stockholders' equity requirements of Sections 1003(a)(ii) and 1003(a)(iii) of the American Company Guide. AIM has until June 11, 2026 to regain compliance with the NYSE's Continued Listings Standards.
Neutral
GlobeNewsWire
1 month ago
AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director
OCALA, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Company's Board of Directors (the “Board”) has, by unanimous vote, appointed David Chemerow as an Independent Director to the Board, effective immediately.
Neutral
GlobeNewsWire
1 month ago
AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer
Several subjects who received the highest dose in Phase 1 will also be included in Phase 2 Several subjects who received the highest dose in Phase 1 will also be included in Phase 2
Neutral
GlobeNewsWire
1 month ago
AIM ImmunoTech Releases Virtual Investor “What This Means Segment”
Tom Equels, CEO of AIM ImmunoTech and Professor Casper H.J. van Eijck, MD, PhD, Pancreato-biliary Surgeon at Erasmus MC, discuss the Phase 1b/2 clinical trial involving AIM's Ampligen® (rintatolimod) and AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of late-stage pancreatic cancer (“DURIPANC”) Watch the “What This Means” segment here
Neutral
GlobeNewsWire
1 month ago
AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024
OCALA, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
Neutral
GlobeNewsWire
1 month ago
AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM's Ampligen® and AstraZeneca's FluMist® to address the recent avian influenza outbreaks
Planned Investigational New Drug application to expand on previous clinical work at the University of Alabama-Birmingham in which administration of Ampligen as an intranasal adjuvant increased immune response, including cross-protection via avian influenza antibody generation in humans Planned Investigational New Drug application to expand on previous clinical work at the University of Alabama-Birmingham in which administration of Ampligen as an intranasal adjuvant increased immune response, including cross-protection via avian influenza antibody generation in humans
Charts implemented using Lightweight Charts™